-
Something wrong with this record ?
Triorganotin Isothiocyanates Affect Migration and Immune Check-point Receptors in Human Triple-negative Breast Carcinoma MDA-MB-231 Cells
L. Hunakova, E. Horvathova, P. Gronesova, P. Bobal, J. Otevrel, J. Brtko,
Language English Country Greece
Document type Journal Article
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
- MeSH
- Apoptosis drug effects MeSH
- Immunophenotyping MeSH
- Isothiocyanates chemistry pharmacology MeSH
- Humans MeSH
- Biomarkers, Tumor * MeSH
- Cell Line, Tumor MeSH
- Organotin Compounds chemistry MeSH
- Cell Movement drug effects MeSH
- DNA Damage drug effects MeSH
- Cell Proliferation drug effects MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Triple Negative Breast Neoplasms metabolism MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND/AIM: Triple-negative breast cancer (TNBC) constitutes 15-20% of all breast carcinomas, affecting younger women more often and has a worse prognosis than other types of breast cancer, due to the combination of more aggressive clinical behavior and lack of molecular targets for therapy. This study assessed the effects of non-genotoxic concentrations of tributyltin isothiocyanate (TBT-ITC) and triphenyltin isothiocyanate (TPT-ITC) on MDA-MB-231 cells. MATERIALS AND METHODS: MTT assay, comet assay, kinetic imaging and flow cytometry were used for analysis of MDA-MB-231 cells. RESULTS: The results showed that 100 nM concentration of TBT-ITC and TPT-ITC, that did not affect viability or DNA integrity, slowed-down migration by CD44 down-regulation. Moreover, both compounds demonstrated immunomodulatory properties, attenuating PD-L1 expression in MDA-MB-231 cells. CONCLUSION: TPT-ITC was more effective in down-regulating CD44 expression and reducing migration than TBT-ITC, while TBT-ITC was more potent in lowering PD-L1 expression in comparison with TPT-ITC.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034419
- 003
- CZ-PrNML
- 005
- 20191010110621.0
- 007
- ta
- 008
- 191007s2019 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/anticanres.13670 $2 doi
- 035 __
- $a (PubMed)31519587
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Hunakova, Luba $u Cancer Research Institute, Biomedical Research Center, University Science Park for Biomedicine, Slovak Academy of Sciences, Bratislava, Slovak Republic exonhun@savba.sk.
- 245 10
- $a Triorganotin Isothiocyanates Affect Migration and Immune Check-point Receptors in Human Triple-negative Breast Carcinoma MDA-MB-231 Cells / $c L. Hunakova, E. Horvathova, P. Gronesova, P. Bobal, J. Otevrel, J. Brtko,
- 520 9_
- $a BACKGROUND/AIM: Triple-negative breast cancer (TNBC) constitutes 15-20% of all breast carcinomas, affecting younger women more often and has a worse prognosis than other types of breast cancer, due to the combination of more aggressive clinical behavior and lack of molecular targets for therapy. This study assessed the effects of non-genotoxic concentrations of tributyltin isothiocyanate (TBT-ITC) and triphenyltin isothiocyanate (TPT-ITC) on MDA-MB-231 cells. MATERIALS AND METHODS: MTT assay, comet assay, kinetic imaging and flow cytometry were used for analysis of MDA-MB-231 cells. RESULTS: The results showed that 100 nM concentration of TBT-ITC and TPT-ITC, that did not affect viability or DNA integrity, slowed-down migration by CD44 down-regulation. Moreover, both compounds demonstrated immunomodulatory properties, attenuating PD-L1 expression in MDA-MB-231 cells. CONCLUSION: TPT-ITC was more effective in down-regulating CD44 expression and reducing migration than TBT-ITC, while TBT-ITC was more potent in lowering PD-L1 expression in comparison with TPT-ITC.
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 12
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a pohyb buněk $x účinky léků $7 D002465
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a poškození DNA $x účinky léků $7 D004249
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunofenotypizace $7 D016130
- 650 _2
- $a isothiokyanatany $x chemie $x farmakologie $7 D017879
- 650 _2
- $a organocínové sloučeniny $x chemie $7 D009947
- 650 _2
- $a triple-negativní karcinom prsu $x metabolismus $7 D064726
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Horvathova, Eva $u Cancer Research Institute, Biomedical Research Center, University Science Park for Biomedicine, Slovak Academy of Sciences, Bratislava, Slovak Republic.
- 700 1_
- $a Gronesova, Paulina $u Cancer Research Institute, Biomedical Research Center, University Science Park for Biomedicine, Slovak Academy of Sciences, Bratislava, Slovak Republic.
- 700 1_
- $a Bobal, Pavel $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
- 700 1_
- $a Otevrel, Jan $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Brno, Czech Republic.
- 700 1_
- $a Brtko, Julius $u Institute of Experimental Endocrinology, Biomedical Research Center, University Science Park for Biomedicine, Slovak Academy of Sciences, Bratislava, Slovak Republic.
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 39, č. 9 (2019), s. 4845-4851
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31519587 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191010111039 $b ABA008
- 999 __
- $a ok $b bmc $g 1451079 $s 1072969
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 39 $c 9 $d 4845-4851 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20191007
